Xeris Biopharma Holdings, Inc.
XERS
$5.96
-$0.11-1.81%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -3.12% | 15.36% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -3.12% | 15.36% | |||
| Cost of Revenue | -3.41% | -0.45% | |||
| Gross Profit | -3.08% | 18.11% | |||
| SG&A Expenses | 11.88% | 2.24% | |||
| Depreciation & Amortization | -0.04% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.95% | 2.05% | |||
| Operating Income | -52.81% | 149.19% | |||
| Income Before Tax | -79.84% | 1,684.38% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -79.84% | 1,684.38% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -79.84% | 1,684.38% | |||
| EBIT | -52.81% | 149.19% | |||
| EBITDA | -44.68% | 102.65% | |||
| EPS Basic | -80.39% | 1,657.89% | |||
| Normalized Basic EPS | -80.34% | 1,637.50% | |||
| EPS Diluted | -84.54% | 1,748.57% | |||
| Normalized Diluted EPS | -79.48% | 1,650.00% | |||
| Average Basic Shares Outstanding | 2.75% | 1.41% | |||
| Average Diluted Shares Outstanding | -1.36% | 1.38% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||